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COVID-19 has rapidly impacted on mortality worldwide.1 There is unprecedented urgency to 
understand who is most at risk of severe outcomes, requiring new approaches for timely 
analysis of large datasets. 
 
Working on behalf of NHS England we created OpenSAFELY: a secure health analytics 
platform covering 40% of all patients in England, holding patient data within the existing data 
centre of a major primary care electronic health records vendor. Primary care records of 
17,278,392 adults were pseudonymously linked to 10,926 COVID-19 related deaths.  
COVID-19 related death was associated with: being male (hazard ratio 1.59, 95%CI 1.53-
1.65); older age and deprivation (both with a strong gradient); diabetes; severe asthma; and 
various other medical conditions. Compared to people with white ethnicity, black and South 
Asian people were at higher risk even after adjustment for other factors (HR 1.48, 1.30-1.69 
and 1.44, 1.32-1.58 respectively).  
 
We have quantified a range of clinical risk factors for COVID-19 related death in the largest 
cohort study conducted by any country to date. OpenSAFELY is rapidly adding further 










On March 11th 2020, the World Health Organisation characterised COVID-19 as a pandemic 
after 118,000 cases and 4,291 deaths were reported in 114 countries.2 As of 6 May (the date 
of latest data availability for this study), cases reached over 3.5 million globally, with more 
than 240,000 deaths attributed to the virus.1 On the same day in the UK, there were 206,715 
confirmed cases, with 30,615 deaths.3  
 
Age and gender are well-established risk factors for severe COVID-19 outcomes, with over 
90% of UK deaths being in people over 60, and 60% in men4. Various pre-existing 
conditions have also been associated with increased risk. For example, the Chinese center 
for disease control and prevention (44,672 patients, 1,023 deaths) reported cardiovascular 
disease, hypertension, diabetes, respiratory disease, and cancers as associated with 
increased risk of death5, but correction for relationships with age was not possible. A UK 
cross-sectional survey describing 16,749 patients hospitalised with COVID-19 showed 
higher risk of death for patients with cardiac, pulmonary and kidney disease, as well as 
malignancy, dementia and obesity (hazard ratios 1.19-1.39 after age and sex correction).6 
Obesity was associated with treatment escalation in a French ITU cohort (n=124) and a New 
York hospital presentation cohort (n=3615).7,8 Risks associated with smoking are unclear.9 10 
11 People from black and minority ethnic (BME) groups are at increased risk of bad 
outcomes from COVID-19, for reasons that are unclear.12,13 
 
Patient care is typically managed through electronic health records (EHR) which are 
commonly used in research. However traditional approaches to EHR analysis rely on 
intermittent extracts of small samples of historic data. Evaluating a rapidly arising novel 
cause of death requires a new approach. We therefore set out to deliver a secure analytics 
platform inside the data centre of major electronic health records vendors, running across 
the full live linked pseudonymised electronic health records of a very large population of 
NHS patients, to determine factors associated with COVID-19 related death in England 










17,278,392 adults were included (Figure 1; cohort description in Table 1). 1,851,868 (11%) 
individuals had non-white ethnicities recorded. There were missing data for body mass index 
(3,751,769, 22%), smoking status (720,923, 4%), ethnicity (4,560,113, 26%), and blood 
pressure (1,715,095, 10%). 10,926 of the study population had COVID-19 related death 
recorded in linked death registration data. 
 
The overall cumulative incidence of death 90 days after study start was <0.01% in those 
aged 18-39 years, rising to 0.67% and 0.44% in men and women respectively aged ≥80 
years (Figure 2). 
 
Associations between patient-level factors and risk of death are shown in Table 2 and Figure 
3. Increasing age was strongly associated with risk, with those ≥80 years having more than 
20-fold increased risk than 50-59 year olds (fully adjusted HR 20.61; 95% CI 18.72-22.70). 
With age fitted as a flexible spline, an approximately log-linear relationship was observed 
(Extended Data Figure A1). Men had higher risk than women (fully adjusted HR 1.59, 1.53-
1.65). These findings are consistent with patterns observed in smaller studies worldwide and 
in the UK.14 
 
All non-white ethnic groups had higher risk than those with white ethnicity: HRs adjusted for 
age and sex only ranged from 1.62-1.90 for Black, South Asian and mixed ethnicities 
compared to white; attenuated to 1.43-1.48 on adjustment for all included risk factors (results 
for more detailed categories are shown in Extended Data Table A1). Non-white ethnicity has 
previously been found to be associated with increased COVID-19 infection and poor 
outcomes.12,13,15 Our findings show that only a small part of the excess risk is explained by 
higher prevalence of medical problems such as cardiovascular disease or diabetes among 
BME people, or higher deprivation.  
 
We found a consistent pattern of increasing risk with greater deprivation, with the most 
deprived quintile having a HR of 1.80 compared to the least deprived, consistent with recent 
national statistics.16 Again, very little of this increased risk was explained by pre-existing 
disease or clinical risk factors, suggesting that other social factors may have an important 
role.  
 
Increasing risks were seen with increasing obesity (BMI >40 fully adjusted HR 1.92, 95% CI 
1.72-2.13), and most comorbidities were associated with higher risk of death, including 
diabetes (with a greater HR for those with recent HbA1c >= 58 mmol/mol), severe asthma 
(defined as asthma with recent use of an oral corticosteroid), respiratory disease, chronic 
heart disease, liver disease, stroke/dementia, other neurological diseases, reduced kidney 
function (with greater HR for lower estimated glomerular filtration rate), autoimmune 
diseases (rheumatoid arthritis, lupus or psoriasis) and other immunosuppressive conditions, 
as per Table 2. Those with a recent (<5 years) history of haematological malignancy had a 
≥2.5-fold increased risk, decreasing slightly after 5 years. For other cancers, increased HRs 
were smaller and mainly with recent diagnoses. History of dialysis or end-stage renal failure 
was associated with increased risk when added in a secondary analysis (HR 3.69, 3.10-
4.39). These findings largely concurred with other data including the UK ISARIC study of 
hospitalised UK patients with COVID-19 that indicated increased risk of death with cardiac, 
pulmonary and kidney disease, malignancy, obesity and dementia,6 and a large Chinese 
study which, though lacking age correction, suggested cardiovascular disease, hypertension, 
diabetes, respiratory disease, and cancers to be associated with increased mortality.5 Our 
findings that severe asthma was associated with higher risk were notable since early data 
suggested underrepresentation of asthma in patients hospitalised or with severe COVID-19 
outcomes.1718 
 
Post-hoc analyses: smoking and hypertension 
Both current and former smoking were associated with higher risk in models adjusted for age 
and sex only, but in the fully adjusted model current smoking was associated with a lower 
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risk (fully adjusted HR 0.89, CI 0.82-0.97), concurring with lower than expected smoking 
prevalences in previous studies among hospitalised patients in China,10 France11 and the 
USA.19 We further explored this post-hoc by adding covariates individually to the age, sex 
and smoking model, and found the change in HR to be largely driven by adjustment for 
chronic respiratory disease (HR 0.98, 0.90-1.06 after adjustment). This and other 
comorbidities could be consequences of smoking, highlighting that the fully adjusted 
smoking HR cannot be interpreted causally due to the inclusion of factors likely to mediate 
smoking effects. We therefore then fitted a model adjusted for demographic factors only 
(age, sex, deprivation, ethnicity), which showed a non-significant positive HR for current 
smoking (HR 1.07, 0.98-1.18). This does not support any postulated protective effect of 
nicotine 9,20 but suggests that any increased risk with current smoking is likely to be small, 
and will need to be clarified as the epidemic progresses and more data accumulate. 
 
We similarly explored the change in the hypertension HR (from 1.08, 1.03-1.13 adjusted for 
age and sex to 0.89, 0.85-0.93 with all covariates included), and found diabetes and obesity 
to be principally responsible for this reduction (HR 0.97, 0.92-1.01 adjusted for age, sex, 
diabetes, obesity). Given the strong association between blood pressure and age we then 
examined an interaction between these variables; this revealed strong evidence of 
interaction (p<0.001) with hypertension associated with higher risk up to age 70 years and 
lower risk at older ages (adjusted HRs 3.11 [1.68-5.71] , 2.75 [1.97-3.83], 2.07 [1.73-2.47], 
1.32 [1.17-1.50], 0.94 [0.86-1.02], 0.73 [0.69-0.78] for ages 18-<40, 40-<50, 50-<60, 60-<70, 
70-<80 and ≥80 respectively). The reasons for the inverse association between hypertension 
and mortality in older individuals are unclear and warrant further investigation including 
detailed examination by frailty, comorbidity and drug exposures in this age group.  
 
Model checking and sensitivity analyses 
The average C-statistic was 0.77. Results were similar when missing data were handled 
using analysis of complete records only, or using multiple imputation (sensitivity analyses: 
Table A2, Extended Data). Non-proportional hazards were detected in the primary model 
(p<0.001).  A sensitivity analysis with earlier administrative censoring at 6th April 2020, 
before which mortality should not have been affected by UK social distancing policies 
introduced in late March, showed no evidence of non-proportional hazards (p=0.83). HRs 
were similar but somewhat larger in magnitude for some covariates, while the association 





This secure analytics platform operating across over 23 million patient records for the 
COVID-19 emergency was used to identify, quantify, and explore risk factors for COVID-19 
related death in the largest cohort study conducted by any country to date. Most 
comorbidities were associated with increased risk, including cardiovascular disease, 
diabetes, respiratory disease including severe asthma, obesity, history of haematological 
malignancy or recent other cancer, kidney, liver, neurological and autoimmune conditions. 
People from South Asian and black groups had a substantially higher risk of death, only 
partially attributable to co-morbidity, deprivation or other risk factors. A strong association 
between deprivation and risk was only partly attributable to co-morbidity or other risk factors.  
 
These analyses provide a preliminary picture of how key demographic characteristics and a 
range of comorbidities, a priori selected as being of interest in COVID-19, are jointly 
associated with poor outcomes. These initial results may be used subsequently to inform the 
development of prognostic models. We caution against interpreting our estimates as causal 
effects. For example, the fully adjusted smoking hazard ratio does not capture the causal 
effect of smoking due to the inclusion of comorbidities which are likely to mediate any effect 
of smoking on COVID-19 death (e.g. COPD). Our study has highlighted a need for carefully 
designed causal analyses specifically focusing on the causal effect of smoking on COVID-19 
death. Similarly, there is a need for analyses exploring the causal relationships underlying 
the associations observed between hypertension and COVID-19 death. 
 
Strengths and weaknesses 
The greatest strengths of this study were speed and size. By building a secure analytics 
platform across routinely collected live clinical data stored in situ we have produced timely 
results from the current records of approximately 40% of the English population. This scale 
allows more precision, on rarer exposures, on multiple risk factors, and rapid detection of 
important signals. Our platform will expand to provide updated analyses over time. Another 
strength is our use of open methods: we pre-specified our analysis plan and shared our full 
analytic code and code lists for review and re-use. We ascertained demographics, 
medications and co-morbidities from full pseudonymised longitudinal primary care records, 
providing substantially more detail than data recorded on admission, and on the total 
population rather than the selected subset presenting at hospital. We censored deaths from 
other causes using ONS data. Analyses were stratified by area to account for known 
geographical differences in incidence of COVID-19. 
 
We also identify important limitations. In our outcome definition, we included clinically 
suspected (non laboratory confirmed) COVID-19, because testing has not always been 
carried out, especially in older patients in care homes. However, this may have incorrectly 
identified some patients as having COVID-19. Some COVID-19 deaths may have been 
misclassified as non-COVID-19, particularly in the early stages of the pandemic, though this 
is likely to have reduced quickly as deaths accumulated, and a degree of outcome 
underascertainment, providing unrelated to patient characteristics, should not have biased 
our hazard ratios. Due to the rarity of the outcome, the associations observed will be driven 
primarily by the profile of risk factors in the included cases. Our findings reflect both an 
individual’s risk of infection, and their risk of dying once infected. We will explore more 
detailed patient trajectories in future research within the OpenSAFELY platform.  
 
Our large population may not be fully representative. We include only 17% of general 
practices in London, where many earlier COVID-19 cases occurred, due to the substantial 
geographic variation in choice of EHR system.. The user interface of electronic health 
records can affect prescribing of certain medicines21–23 so it is possible that coding may vary 
between systems.  
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Primary care records, though detailed and longitudinal, can be incomplete for data on risk 
factors and other covariates. Ethnicity was missing for approximately 26%, but was broadly 
representative;24 there were also missing data on obesity and smoking. Sensitivity analyses 
found our estimates were robust to our assumptions around missing data.  
 
Non-proportional hazards could be due to very large numbers or unmeasured covariates. 
However, rapid changes in social behaviours (social distancing, shielding) and changes in 
the burden of infection may also have affected patient groups differentially. The larger 
hazard ratios seen for several covariates in a sensitivity analysis with earlier censoring (soon 
after social distancing and shielding policies were introduced) are consistent with more at-
risk patients being more compliant with these policies. In contrast, the risk associated with 
deprivation may have increased over time. Subsequent analyses will further explore 
changes before and after national initiatives around COVID-19.  
 
Policy Implications and Interpretation 
The UK has a policy of recommending shielding (staying at home at all times and avoiding 
any face to face contact) for groups identified as being extremely vulnerable to COVID-19 on 
the basis of pre-existing medical conditions.25 We were able to evaluate the association 
between most of these conditions and death from COVID-19, and confirmed increased 
mortality risks, supporting the targeted use of additional protection measures for people in 
these groups. We have demonstrated - for the first time - that only a small part of the 
substantially increased risks of COVID-19 related death among non-white groups and 
among people living in more deprived areas can be attributed to existing disease. Improved 
strategies to protect people in these groups are urgently needed.26 These might include 
specific consideration of BME groups in shielding guidelines and work-place policies. 
Subsequent studies are needed to investigate the interplay of additional factors we were 
unable to explore, including employment, access to personal protective equipment and 
related risk of exposure to infection and household density.  
 
The UK has an unusually large volume of very detailed longitudinal patient data, especially 
through primary care. We believe the UK has a responsibility to the global community to 
make good use of such data. OpenSAFELY demonstrates at an unprecedented scale that 
this can be done securely, transparently, and rapidly. We will enhance the OpenSAFELY 
platform to further inform the global response to the COVID-19 emergency.  
 
Future Research 
The underlying causes of higher risk of COVID-19 related death among those from non-
white backgrounds, and deprived areas, require further exploration; we would suggest 
collecting data on occupational exposure and living conditions as first steps. The statistical 
power offered by our approach means that associations with less common risk factors can 
be robustly assessed in more detail, at the earliest possible date, as the pandemic 
progresses. We will therefore update our findings and address smaller risk groups as new 
cases arise over time. The open source reusable codebase on OpenSAFELY supports 
rapid, secure and collaborative development of new analyses: we are currently conducting 
expedited studies on the impact of various medical treatments and population interventions 
on the risk of COVID-19 infection, ITU admission, and death, alongside other observational 
analyses. OpenSAFELY is rapidly scalable for additional NHS patients’ records, with new 




We generated early insights into risk factors for COVID-19 related death using an 
unprecedented scale of 17 million patients’ detailed primary care records, maintaining 
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MAIN DISPLAY ITEM LEGENDS 
 
Table 1. Cohort description with number of COVID-19 deaths by potential risk factors 
 
Footnote: * ocs= oral corticosteroid use, recent is <1 year before baseline, **classification by 
HbA1c based on measures within 15 months before baseline, ***GFR= glomerular filtration 
rate (ml/min/1.73m2), from most recent serum creatinine measure 
 
 
Table 2. Hazard Ratios (HRs) and 95% confidence intervals (CI) for COVID-19 death 
 
Footnote: Models adjusted for age using a 4-knot cubic spline age spline, except for 
estimation of age group hazard ratios. *Ethnicity hazard ratios estimated from a model 
restricted to those with recorded ethnicity. **OCS = oral corticosteroids. Recent OCS use 
defined as in the year before baseline. ***HbA1c classification based on latest measure 
within 15 months before baseline. ****GFR = glomerular filtration rate in ml/min/1.73m2, 
based on most recent serum creatinine measure 
 
 
Figure 1. Flow diagram of cohort with numbers excluded at different stages and 
identification of cases for the main endpoints. 
 
 
Figure 2. Kaplan-Meier plots for COVID-19 related death over time by age and sex  
 
Figure 3. Estimated Hazard Ratios (shown on a log scale) for each potential risk factor from 
a multivariable Cox model  
 
Footnote: Error bars represent limits of the 95% confidence interval for the hazard ratio. 
Obese class I: 30-34.9kg/m2, class II: 35-39.9kg/m2, class III: >=40kg/m2. OCS = oral 
corticosteroid. All HRs are adjusted for all other factors listed other than ethnicity. Ethnicity 
estimates are from a separate model among those with complete ethnicity data, and are fully 
adjusted for other covariates. Total N = 17,278,392 for non-ethnicity models, and 12,718,279 
for ethnicity model. 
 
 
EXTENDED DATA LEGENDS 
 
Table A1: Adjusted hazard ratios for detailed ethnicity categories 
 
Estimated from a model restricted to those with recorded ethnicity, adjusted for age using a 
4-knot cubic spline age spline, sex, BMI, smoking, IMD quintile, hypertension/high blood 
pressure, asthma, chronic heart disease, diabetes, non-haematological cancer , 
haematological malignancy, reduced kidney function, liver disease, stroke/dementia, other 
neurological disease, organ transplant, asplenia, rheumatoid/lupus/psoriasis, other 
immunosuppressive condition; all categorisations are as in the primary analysis. 
 
Table A2. Hazard Ratios (HRs) and 95% confidence intervals (CI) in sensitivity analyses 
 
FOOTNOTES: Models adjusted for age using a 4-knot cubic spline age spline, except for 
estimation of age group hazard ratios. *Ethnicity hazard ratios in primary analysis estimated 
from a model restricted to those with recorded ethnicity. **OCS = oral corticosteroids. 
Recent OCS use defined as in the year before baseline. ***HbA1c classification based on 





Figure A1. Estimated log hazard ratio by age in years  
 
Footnote: From the primary fully adjusted model containing a 4-knot cubic spline for age, 
and adjusted for all covariates listed in Table 2 except for ethnicity. 
 
 






Study design  
We conducted a cohort study using national primary care electronic health record data linked 
to COVID-19 death data (see Data Source). The cohort study began on 1st February 2020, 
chosen as a date several weeks prior to the first reported COVID-19 deaths and the day 
after the second laboratory confirmed case;27 and ended on 6th May 2020. The cohort 
explores risk among the general population rather than in a population infected with SARS-
COV-2. Therefore, all patients were included irrespective of any SARS-COV-2 test results.  
 
Data Source  
We used patient data from general practice (GP) records managed by the GP software 
provider The Phoenix Partnership (TPP), linked to Office for National Statistics (ONS) death 
data. ONS data includes information on all deaths, including  COVID-19 related death, 
defined as a COVID-19 ICD-10 code mentioned anywhere on the death certificate and non-
COVID-19 death, which was used for censoring.  
 
The data were accessed, linked and analysed using OpenSAFELY, a new data analytics 
platform created to address urgent questions relating to the epidemiology and treatment of 
COVID-19 in England. OpenSAFELY provides a secure software interface that allows 
detailed pseudonymised primary care patient records to be analysed in near real-time where 
they already reside, hosted within the EHR vendor’s highly secure data centre, to minimise 
the re-identification risks when data are transported off-site; other smaller datasets are linked 
to these data within the same environment using a matching pseudonym derived from the 
NHS number. More information can be found on https://opensafely.org/.  
The dataset analysed with OpenSAFELY is based on 24 million currently registered patients 
(approximately 40% of the English population) from GP surgeries using the TPP SystmOne 
electronic health record system. SystmOne is a secure centralised EHR used in English 
clinical practice since 1998; it records data entered (in real time) by GPs and practice staff 
during routine primary care. The system is accredited under the NHS approved systems 
framework for General Practice.28,29 Data extracted from TPP SystmOne have previously 
been used in medical research, as part of the ResearchOne dataset.30,31 From this EHR a 
pseudonymised dataset was created for OpenSAFELY consisting of 20 billion rows of 
structured data including for example pseudonymised patients’ diagnoses, medications, 
physiological parameters, and prior investigations [Extended Data Figure A2, Level 1].  All 
OpenSAFELY data processing took place on TPP’s servers; external data providers 
securely transferred pseudoymised data (such as COVID-19 related death from ONS) for 
linkage to OpenSAFELY [Extended Data Figure A2, Level 2]; study definitions developed in 
Python on GitHub were pulled into the OpenSAFELY infrastructure, and used to create a 
study dataset of one row per patient [Extended Data Figure A2, Level 3]. Statistical code 
was developed using synthetic data and used to analyse the study dataset; this included 
code to check data ranges, to check consistency of data columns, and to produce 
descriptive statistics for comparison with expected disease prevalences to ensure validity, as 
well as code to fit our analysis models. Only two authors (KB/AJW) accessed OpenSAFELY 
to run code; no pseudonymised patient-level data were ever removed from TPP 
infrastructure; only aggregated, anonymous, manually checked study results were released 
for publication [Extended Data Figure A2, Level 4], All code for data management and 
analysis is archived online (see Code Availability, below). 
 
Study Population and Observation Period 
Our study population consisted of all adults (males and females 18 years and above) 
currently registered as active patients in a TPP general practice in England on 1st February 
2020. To be included in the study, participants were required to have at least 1 year of prior 
follow-up in the GP practice to ensure that baseline patient characteristics could be 
adequately captured, and to have recorded sex, age, and deprivation (see covariates, 
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below).32 Patients were observed from the 1st of February 2020 and were followed until the 
first of either their death date (whether COVID-19 related or due to other causes) or the 
study end date, 6th May 2020. For this analysis, ONS death data were available to 11th May 
2020, but we used an earlier censor date to allow for delays in reporting in the last few days 
of available data. 
 
Outcomes  
The outcome was death among people with COVID-19, ascertained from ONS death 




Potential risk factors included: health conditions listed in UK guidance on “higher risk” 
groups;33 other common conditions which may cause immunodeficiency inherently or 
through medication (cancer and common autoimmune conditions); and emerging risk factors 
for severe outcomes among COVID-19 cases (such as raised blood pressure).  
 
Age, sex, body mass index (BMI; kg/m2), and smoking status were considered as potential 
risk factors. Where categorised, age groups were: 18-<40, 40-<50, 50-<60, 60-<70, 70-<80, 
80+ years. BMI was ascertained from weight measurements within the last 10 years, 
restricted to those taken when the patient was over 16 years old. Obesity was grouped using 
categories derived from the World Health Organisation classification of BMI: no evidence of 
obesity <30 kg/m2; obese I 30-34.9; obese II 35-39.9; obese III 40+. Smoking status was 
grouped into current, former and never smokers.  
 
The following comorbidities were also considered potential risk factors: asthma, other 
chronic respiratory disease, chronic heart disease, diabetes mellitus, chronic liver disease, 
chronic neurological diseases, common autoimmune diseases (Rheumatoid Arthritis (RA), 
Systemic Lupus Erythematosus (SLE) or psoriasis), solid organ transplant, asplenia, other 
immunosuppressive conditions, cancer, evidence of reduced kidney function, and raised 
blood pressure or a diagnosis of hypertension. 
 
Disease groupings followed national guidance on risk of influenza infection,34 therefore 
“chronic respiratory disease (other than asthma)” included COPD, fibrosing lung disease, 
bronchiectasis or cystic fibrosis; chronic heart disease included chronic heart failure, 
ischaemic heart disease, and severe valve or congenital heart disease likely to require 
lifelong follow-up. Chronic neurological conditions were separated into diseases with a likely 
cardiovascular aetiology (stroke, TIA, dementia) and conditions in which respiratory function 
may be compromised such as motor neurone disease, myasthenia gravis, multiple sclerosis, 
Parkinson's disease, cerebral palsy, quadriplegia or hemiplegia, and progressive cerebellar 
disease. Asplenia included splenectomy or a spleen dysfunction, including sickle cell 
disease. Other immunosuppressive conditions included HIV or a condition inducing 
permanent immunodeficiency ever diagnosed, or aplastic anaemia or temporary 
immunodeficiency recorded within the last year. Haematological malignancies were 
considered separately from other cancers to reflect the immunosuppression associated with 
haematological malignancies and their treatment. Kidney function was ascertained from the 
most recent serum creatinine measurement, where available, converted into estimated 
glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation,35 with reduced kidney function grouped into defined as 
eGFR 30-<60 or <30 mL/min/1.73m2. History of kidney dialysis or end-stage renal failure 
was separately explored in a secondary analysis. Raised blood pressure (BP) was defined 
as either a prior coded diagnosis of hypertension or the most recent recording indicating 
systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg. 
 
Asthma was grouped by use of oral corticosteroids as an indication of severity. Diabetes was 
grouped according to the most recent Hba1c measurement within the last 15 months (Hba1c 
14 
<58 mmols/mol, ≥58 mmols/mol, no recent measure available). Cancer was grouped by time 
since the first diagnosis (within the last year, 2-<5 years, ≥5 years). 
  
Other covariates considered as potential upstream risk factors were deprivation and 
ethnicity. Deprivation was measured by the Index of Multiple Deprivation (IMD, in quintiles, 
with higher values indicating greater deprivation), derived from the patient’s postcode at 
lower super output area level for a high degree of precision. Ethnicity was grouped into 
White, Black, South Asian, Mixed, or Other. In sensitivity analyses, a more detailed grouping 
of ethnicity was explored.  The Sustainability and Transformation Partnership (STP, an NHS 
administrative region) of the patient’s general practice was included as an additional 
adjustment for geographical variation in infection rates across the country.  
 
Information on all covariates were obtained from primary care records by searching TPP 
SystmOne records for specific coded data. TPP SystmOne allows users to work with the 
SNOMED-CT clinical terminology, using a GP subset of SNOMED-CT codes. This subset 
maps on to the native Read version 3 (CTV3) clinical coding system that SystmOne is built 
on. Medicines are entered or prescribed in a format compliant with the NHS Dictionary of 
Medicines and Devices (dm+d),36 a local UK extension library of SNOMED. Code lists for 
particular underlying conditions and medicines were compiled from a variety of sources. 
These include BNF codes from OpenPrescribing.net, published codelists for asthma,37–39 
immunosuppression,40–42 psoriasis,43 SLE,44 RA45,46 and cancer,47,48 and Read Code 2 lists 
designed specifically to describe groups at increased risk of influenza infection.18 Read Code 
2 lists were added to with SNOMED codes and cross-checked against NHS QOF registers, 
then translated into CTV3 with manual curation. Decisions on every code list were 
documented and final lists reviewed by at least two authors. Detailed information on 
compilation and sources for every individual codelist is available at 
https://codelists.opensafely.org/ and the lists are available for inspection and re-use by the 
broader research community.49  
 
Statistical Analysis 
Patient numbers are depicted in a flowchart. The Kaplan-Meier failure function was 
estimated by age group and sex. For each potential risk factor, a Cox proportional hazards 
model was fitted, with days in study as the timescale, stratified by geographic area (STP), 
and adjusted for sex and age modelled using restricted cubic splines. Violations of the 
proportional hazards assumption were explored by testing for a zero slope in the scaled 
Schoenfeld residuals. All potential risk factors, including age (again modelled as a spline), 
sex, BMI, smoking, index of multiple deprivation quintile, and comorbidities listed above were 
then included in a single multivariable Cox proportional hazards model, stratified by STP. 
Hazard ratios from the age/sex adjusted and fully adjusted models are reported with 95% 
confidence intervals. Models were also refitted with age group fitted as a categorical variable 
in order to obtain hazard ratios by age group.  
 
In the primary analysis, those with missing BMI were assumed non-obese and those with 
missing smoking information were assumed to be non-smokers on the assumption that both 
obesity and smoking would be likely to be recorded if present. A sensitivity analysis was run 
among those with complete BMI and smoking data only. Ethnicity was omitted from the main 
multivariable model due to 26% of individuals having missing data; hazard ratios for ethnicity 
were therefore obtained from a separate model among individuals with complete ethnicity 
only. Hazard ratios for other risk factors, adjusted for ethnicity, were also obtained from this 
model and are presented in the sensitivity analyses to allow assessment of whether 
estimates may have been distorted by ethnicity in the primary model. We conducted an 
additional sensitivity analysis using a population-calibrated imputation approach to handle 
missing ethnicity,50,51 with marginal proportions of each ethnicity group within each of nine 
broad geographical regions of England (East, East Midlands, London, North East, North 
West, South East, South West, West Midlands, Yorkshire and The Humber) taken from 
Annual Population Survey (APS) data (pooled 2014-2016).52 Five imputed datasets were 
created with estimated hazard ratios combined using Rubin’s rules.  
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The C-statistic was calculated as a measure of model discrimination. Due to computational 
time, this was estimated by randomly sampling 5000 patients with and without the outcome 
and calculating the C-statistic using the random sample, repeating this 10 times and taking 
the average C-statistic.  
 
All p-values presented are two-sided. 
 
Information governance and ethics  
NHS England is the data controller; TPP is the data processor; and the key researchers on 
OpenSAFELY are acting on behalf of NHS England. This implementation of OpenSAFELY is 
hosted within the TPP environment which is accredited to the ISO 27001 information security 
standard and is NHS IG Toolkit compliant;53,54 patient data has been pseudonymised for 
analysis and linkage using industry standard cryptographic hashing techniques; all 
pseudonymised datasets transmitted for linkage onto OpenSAFELY are encrypted; access 
to the platform is via a virtual private network (VPN) connection, restricted to a small group 
of researchers, their specific machine and IP address; the researchers hold contracts with 
NHS England and only access the platform to initiate database queries and statistical 
models; all database activity is logged; only aggregate statistical outputs leave the platform 
environment following best practice for anonymisation of results such as statistical disclosure 
control for low cell counts.55 The OpenSAFELY research platform adheres to the data 
protection principles of the UK Data Protection Act 2018 and the EU General Data Protection 
Regulation (GDPR) 2016. In March 2020, the Secretary of State for Health and Social Care 
used powers under the UK Health Service (Control of Patient Information) Regulations 2002 
(COPI) to require organisations to process confidential patient information for the purposes 
of protecting public health, providing healthcare services to the public and monitoring and 
managing the COVID-19 outbreak and incidents of exposure.56 Taken together, these 
provide the legal bases to link patient datasets on the OpenSAFELY platform. GP practices, 
from which the primary care data are obtained, are required to share relevant health 
information to support the public health response to the pandemic, and have been informed 
of the OpenSAFELY analytics platform. This study was approved by the Health Research 
Authority (REC reference 20/LO/0651) and by the LSHTM Ethics Board (reference 21863).  
 
Data Availability  
All data were linked, stored and analysed securely within the OpenSAFELY platform 
https://opensafely.org/. All code is shared openly for review and re-use under MIT open 
license. Detailed pseudonymised patient data is potentially re-identifiable and therefore not 
shared. We rapidly delivered the OpenSAFELY data analysis platform without prior funding 
to deliver timely analyses on urgent research questions in the context of the global Covid-19 
health emergency: now that the platform is established we are developing a formal process 
for external users to request access in collaboration with NHS England; details of this 
process will be published shortly on OpenSAFELY.org. 
 
Code Availability  
Data management was performed using Python 3.8 and SQL, with analysis carried out using 
Stata 16.1 / Python. All code for data management and analysis is archived online at 
https://github.com/opensafely/risk-factors-research. All clinical and medicines codelists are 
openly available for inspection and reuse at https://codelists.opensafely.org/.  
 
Patient and Public Involvement 
Patients were not formally involved in developing this specific study design. We have 
developed a publicly available website https://opensafely.org/ allowing any patient or 
member of the public to contact us regarding this study or the broader OpenSAFELY project. 
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Table 1. Cohort description with number of COVID-19 deaths by potential risk factors 
Characteristic Category N (column %) Number of COVID-19 deaths (% within stratum) 
Total  17,278,392 (100.0) 10,926 (0.06) 
Age 18-<40 5,914,384 (34.2) 54 (0.00) 
 40-<50 2,849,984 (16.5) 140 (0.00) 
 50-<60 3,051,110 (17.7) 522 (0.02) 
 60-<70 2,392,392 (13.8) 1,101 (0.05) 
 70-<80 1,938,842 (11.2) 2,635 (0.14) 
 80+ 1,131,680 (6.5) 6,474 (0.57) 
Sex Female 8,647,989 (50.1) 4,764 (0.06) 
 Male 8,630,403 (49.9) 6,162 (0.07) 
BMI (kg/m2) <18.5 310,721 (1.8) 522 (0.17) 
 18.5-24.9 4,763,150 (27.6) 3,364 (0.07) 
 25-29.9 4,682,906 (27.1) 3,068 (0.07) 
 30-34.9 (Obese class I) 2,384,406 (13.8) 1,813 (0.08) 
 35-39.9 (Obese class II) 922,398 (5.3) 762 (0.08) 
 ≥40 (Obese class III) 463,042 (2.7) 379 (0.08) 
 Missing 3,751,769 (21.7) 1,018 (0.03) 
Smoking Never 7,924,739 (45.9) 3,598 (0.05) 
 Former 5,690,966 (32.9) 6,531 (0.11) 
 Current 2,941,764 (17.0) 708 (0.02) 
 Missing 720,923 (4.2) 89 (0.01) 
Ethnicity White 10,866,411 (62.9) 7,119 (0.07) 
 Mixed 169,697 (1.0) 62 (0.04) 
 South Asian 1,022,130 (5.9) 608 (0.06) 
 Black 339,909 (2.0) 250 (0.07) 
 Other 320,132 (1.9) 110 (0.03) 
 Missing 4,560,113 (26.4) 2,777 (0.06) 
IMD quintile 1 (least deprived) 3,497,154 (20.2) 1,908 (0.05) 
 2 3,476,668 (20.1) 2,030 (0.06) 
 3 3,483,668 (20.2) 2,114 (0.06) 
 4 3,480,459 (20.1) 2,388 (0.07) 
 5 (most deprived) 3,340,443 (19.3) 2,486 (0.07) 
Blood pressure Normal 3,804,148 (22.0) 2,487 (0.07) 
 Elevated 2,482,710 (14.4) 1,899 (0.08) 
 High Stage 1 5,548,198 (32.1) 3,281 (0.06) 
 High Stage 2 3,728,241 (21.6) 3,229 (0.09) 
 Missing 1,715,095 (9.9) 30 (0.00) 
High bp or diagnosed 
hypertension  5,925,492 (34.3) 8,049 (0.14) 
Respiratory disease ex 
asthma  703,917 (4.1) 2,240 (0.32) 
Asthma* With no recent ocs use 2,454,403 (14.2) 1,211 (0.05) 
 With recent ocs use 291,670 (1.7) 335 (0.11) 
Chronic heart disease  1,167,455 (6.8) 3,811 (0.33) 
Diabetes** With HbA1c<58 mmol/mol 1,038,082 (6.0) 2,391 (0.23) 
 With HbA1c>=58 mmol/mol 486,491 (2.8) 1,254 (0.26) 
 With no recent HbA1c measure 193,993 (1.1) 444 (0.23) 
Cancer (non-
haematological) Diagnosed < 1 year ago 79,964 (0.5) 220 (0.28) 
 Diagnosed 1-4.9 years ago 234,186 (1.4) 449 (0.19) 
 Diagnosed ≥5 years ago 542,320 (3.1) 1,125 (0.21) 
Haematological malignancy Diagnosed < 1 year ago 8,704 (0.1) 43 (0.49) 
 Diagnosed 1-4.9 years ago 27,742 (0.2) 120 (0.43) 
 Diagnosed ≥5 years ago 63,460 (0.4) 173 (0.27) 
Reduced kidney function*** Estimated GFR 30-60 1,007,383 (5.8) 3,987 (0.40) 
 Estimated GFR <30 78,093 (0.5) 864 (1.11) 
Kidney dialysis  23,978 (0.1) 192 (0.80) 
Liver disease  100,017 (0.6) 181 (0.18) 
Stroke/dementia  390,002 (2.3) 2,423 (0.62) 
Other neurological disease  170,448 (1.0) 665 (0.39) 
Organ transplant  20,001 (0.1) 69 (0.34) 
Asplenia  27,917 (0.2) 40 (0.14) 
Rheumatoid/Lupus/ 
Psoriasis  878,475 (5.1) 962 (0.11) 
Other immunosuppressive 
condition  278,948 (1.6) 69 (0.02) 
* ocs= oral corticosteroid use, recent is <1 year before baseline, **classification by HbA1c based on measures within 15 
months before baseline, ***GFR= glomerular filtration rate (ml/min/1.73m2), from most recent serum creatinine measure 
 
 
Table 2. Hazard Ratios (HRs) and 95% confidence intervals (CI) for COVID-19 death 
Characteristic Category COVID-19 Death HR (95% CI)  
  Age-sex adj Fully adj 
Age 18-<40 0.05 (0.04-0.07) 0.06 (0.04-0.08) 
 40-<50 0.28 (0.23-0.33) 0.30 (0.25-0.36) 
 50-<60 1.00 (ref) 1.00 (ref) 
 60-<70 2.79 (2.52-3.10) 2.40 (2.16-2.66) 
 70-<80 8.62 (7.84-9.46) 6.08 (5.52-6.69) 
 80+ 38.29 (35.02-41.87) 20.61 (18.72-22.70) 
Sex Female 1.00 (ref) 1.00 (ref) 
 Male 1.78 (1.71-1.85) 1.59 (1.53-1.65) 
BMI Not obese 1.00 (ref) 1.00 (ref) 
 30-34.9kg/m2 (Obese class I) 1.23 (1.17-1.29) 1.05 (1.00-1.11) 
 35-39.9kg/m2 (Obese class II) 1.70 (1.57-1.83) 1.40 (1.30-1.52) 
 ≥40 kg/m2 (Obese class III) 2.36 (2.12-2.62) 1.92 (1.72-2.13) 
Smoking Never 1.00 (ref) 1.00 (ref) 
 Former 1.57 (1.51-1.64) 1.19 (1.14-1.24) 
 Current 1.23 (1.13-1.33) 0.89 (0.82-0.97) 
Ethnicity* White 1.00 (ref) 1.00 (ref) 
 Mixed 1.62 (1.26-2.09) 1.43 (1.11-1.85) 
 South Asian 1.72 (1.58-1.88) 1.44 (1.32-1.58) 
 Black 1.90 (1.67-2.17) 1.48 (1.30-1.69) 
 Other 1.37 (1.13-1.66) 1.33 (1.10-1.61) 
IMD quintile 1 (least deprived) 1.00 (ref) 1.00 (ref) 
 2 1.15 (1.08-1.23) 1.12 (1.05-1.19) 
 3 1.31 (1.23-1.39) 1.23 (1.15-1.30) 
 4 1.67 (1.57-1.77) 1.51 (1.42-1.61) 
 5 (most deprived) 2.09 (1.96-2.22) 1.80 (1.69-1.91) 
Blood pressure Normal 1.00 (ref) 1.00 (ref) 
 High bp or diagnosed hypertension 1.08 (1.03-1.13) 0.89 (0.85-0.93) 
Respiratory disease ex 
asthma  2.03 (1.94-2.13) 1.63 (1.55-1.71) 
Asthma (vs none)** With no recent OCS use 1.09 (1.03-1.16) 0.99 (0.93-1.05) 
 With recent OCS use 1.47 (1.32-1.64) 1.13 (1.01-1.26) 
Chronic heart disease  1.70 (1.63-1.77) 1.17 (1.12-1.22) 
Diabetes (vs none)*** With HbA1c<58 mmol/mol 1.64 (1.57-1.72) 1.31 (1.24-1.37) 
 With HbA1c>=58 mmol/mol 2.76 (2.60-2.93) 1.95 (1.83-2.07) 
 With no recent HbA1c measure 2.28 (2.07-2.52) 1.90 (1.72-2.09) 
    
Cancer (non-haematological, 
vs none) Diagnosed < 1 year ago 1.95 (1.70-2.23) 1.72 (1.50-1.97) 
 Diagnosed 1-4.9 years ago 1.30 (1.18-1.42) 1.15 (1.05-1.27) 
 Diagnosed ≥5 years ago 1.01 (0.95-1.08) 0.96 (0.91-1.03) 
Haematological malignancy 
(vs none) Diagnosed < 1 year ago 3.24 (2.40-4.37) 2.82 (2.09-3.81) 
 Diagnosed 1-4.9 years ago 2.72 (2.28-3.26) 2.47 (2.06-2.96) 
 Diagnosed ≥5 years ago 1.77 (1.53-2.06) 1.62 (1.39-1.88) 
Reduced kidney function (vs 
none)**** Estimated GFR 30-60 1.55 (1.49-1.62) 1.33 (1.28-1.40) 
 Estimated GFR <30 3.59 (3.33-3.87) 2.52 (2.33-2.72) 
Liver disease  2.42 (2.09-2.81) 1.75 (1.51-2.03) 
Stroke/dementia  2.65 (2.52-2.77) 2.16 (2.06-2.27) 
Other neurological disease  3.20 (2.96-3.47) 2.58 (2.38-2.79) 
Organ transplant  6.29 (4.96-7.97) 3.55 (2.79-4.52) 
Asplenia  1.67 (1.22-2.27) 1.34 (0.98-1.83) 
Rheumatoid/Lupus/ Psoriasis  1.27 (1.19-1.36) 1.19 (1.11-1.27) 
Other immunosuppressive 
condition  2.08 (1.64-2.63) 1.70 (1.34-2.16) 
Models adjusted for age using a 4-knot cubic spline age spline, except for estimation of age group hazard ratios. 
*Ethnicity hazard ratios estimated from a model restricted to those with recorded ethnicity. **OCS = oral 
corticosteroids. Recent OCS use defined as in the year before baseline. ***HbA1c classification based on latest 
measure within 15 months before baseline. ****GFR = glomerular filtration rate in ml/min/1.73m2, based on most 




Population registered with a 
general practice using TPP 
software on 1st February 2020
N = 23,600,617
Adults aged 18 or over
N = 17,421,033
At least 1 year of follow-up 
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N = 17,278,392
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Table A1: Adjusted hazard ratios for detailed ethnicity categories 
Ethnicity 
Fully adjusted 
hazard ratio* 95% CI 
British or mixed British 1.00 (ref) 
Irish 1.16 (0.96-1.41) 
Other White 0.87 (0.79-0.97) 
Mixed ethnicity 1.42 (1.11-1.83) 
Indian or British Indian 1.40 (1.23-1.59) 
Pakistani or British Pakistani 1.24 (1.05-1.46) 
Bangladeshi or British Bangladeshi 1.84 (1.35-2.49) 
Other Asian 1.73 (1.44-2.08) 
Caribbean 1.28 (1.07-1.53) 
African 1.78 (1.42-2.23) 
Other Black 1.73 (1.24-2.41) 
Chinese 1.22 (0.81-1.84) 
Other 1.35 (1.09-1.67) 
 
Estimated from a model restricted to those with recorded ethnicity, adjusted for age using a 4-knot cubic spline age spline, sex, 
BMI, smoking, IMD quintile, hypertension/high blood pressure, asthma, chronic heart disease, diabetes, non-haematological 
cancer , haematological malignancy, reduced kidney function, liver disease, stroke/dementia, other neurological disease, organ 
transplant, asplenia, rheumatoid/lupus/psoriasis, other immunosuppressive condition; all categorisations are as in the primary 
analysis. 
Table A2. Hazard Ratios (HRs) and 95% confidence intervals (CI) in sensitivity analyses 
  Fully adjusted HR and 95% CI 












N outcome events 
in analysis  10926 2816 9880 8149  
Age 18-<40 0.06 (0.04-0.08) 0.07 (0.04-0.12) 0.07 (0.05-0.10) 0.06 (0.05-0.09) 0.06 (0.04-0.07) 
 40-<50 0.30 (0.25-0.36) 0.32 (0.23-0.45) 0.30 (0.24-0.37) 0.29 (0.24-0.36) 0.29 (0.24-0.35) 
 50-<60 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 60-<70 2.40 (2.16-2.66) 2.55 (2.11-3.08) 2.38 (2.13-2.67) 2.37 (2.11-2.67) 2.43 (2.19-2.70) 
 70-<80 6.08 (5.52-6.69) 5.84 (4.89-6.99) 5.96 (5.38-6.61) 6.06 (5.43-6.76) 6.24 (5.66-6.87) 
 80+ 20.61 (18.72-22.70) 14.68 (12.24-17.59) 19.97 (18.01-22.15) 20.20 (18.09-22.55) 21.19 (19.23-23.34) 
Sex Female 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 Male 1.59 (1.53-1.65) 1.90 (1.75-2.05) 1.65 (1.58-1.72) 1.54 (1.47-1.61) 1.57 (1.52-1.64) 
BMI Not obese 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref)  
 30-34.9kg/m2 (Obese class I) 1.05 (1.00-1.11) 1.30 (1.18-1.43) 1.07 (1.02-1.13) 1.05 (0.99-1.11) 1.06 (1.00-1.11) 
 35-39.9kg/m2 (Obese class II) 1.40 (1.30-1.52) 1.57 (1.36-1.81) 1.45 (1.34-1.57) 1.41 (1.30-1.54) 1.42 (1.32-1.54) 
 
≥40 kg/m2 
(Obese class III) 
1.92 (1.72-2.13) 2.70 (2.26-3.21) 1.99 (1.79-2.21) 1.92 (1.70-2.17) 1.96 (1.76-2.18) 
Smoking Never 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 Former 1.19 (1.14-1.24) 1.27 (1.17-1.39) 1.18 (1.13-1.24) 1.22 (1.16-1.29) 1.23 (1.18-1.29) 
 Current 0.89 (0.82-0.97) 0.93 (0.79-1.09) 0.91 (0.83-0.99) 0.93 (0.84-1.02) 0.93 (0.85-1.01) 
Ethnicity* White 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 Mixed 1.43 (1.11-1.85) 1.01 (0.60-1.72) 1.38 (1.05-1.80) 1.43 (1.11-1.85) 1.44 (1.06-1.95) 
 South Asian 1.44 (1.32-1.58) 1.62 (1.38-1.91) 1.51 (1.38-1.66) 1.44 (1.32-1.58) 1.48 (1.33-1.65) 
 Black 1.48 (1.30-1.69) 1.76 (1.41-2.20) 1.48 (1.28-1.70) 1.48 (1.30-1.69) 1.53 (1.32-1.77) 
 Other 1.33 (1.10-1.61) 1.84 (1.37-2.47) 1.40 (1.15-1.70) 1.33 (1.10-1.61) 1.34 (1.12 1.61) 
IMD quintile 1 (least deprived) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 2 1.12 (1.05-1.19) 0.96 (0.85-1.08) 1.12 (1.05-1.19) 1.16 (1.08-1.25) 1.12 (1.05-1.19) 
 3 1.23 (1.15-1.30) 1.00 (0.88-1.13) 1.23 (1.15-1.31) 1.26 (1.17-1.36) 1.21 (1.14-1.29) 
 4 1.51 (1.42-1.61) 1.26 (1.11-1.41) 1.51 (1.42-1.61) 1.54 (1.43-1.66) 1.48 (1.39-1.57) 
 5 (most deprived) 1.80 (1.69-1.91) 1.41 (1.25-1.60) 1.80 (1.69-1.93) 1.77 (1.64-1.91) 1.72 (1.61-1.84) 
Blood pressure Normal 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 
 
High bp or 
diagnosed 
hyper-tension 
0.89 (0.85-0.93) 0.95 (0.87-1.04) 0.88 (0.84-0.92) 0.91 (0.86-0.96) 0.89 (0.85-0.93) 
Respiratory disease 
ex asthma  1.63 (1.55-1.71) 1.86 (1.69-2.04) 1.59 (1.51-1.67) 1.65 (1.56-1.75) 1.64 (1.56-1.72) 
Asthma (vs none)** With no recent OCS use 0.99 (0.93-1.05) 1.08 (0.96-1.21) 0.97 (0.91-1.04) 0.94 (0.87-1.00) 0.98 (0.93-1.05) 
 With recent OCS use 1.13 (1.01-1.26) 1.38 (1.13-1.67) 1.09 (0.97-1.22) 1.08 (0.95-1.22) 1.11 (0.99-1.24) 
Chronic heart 




mmol/mol 1.31 (1.24-1.37) 1.38 (1.26-1.52) 1.29 (1.23-1.36) 1.28 (1.21-1.35) 1.27 (1.21-1.33) 
 WithHbA1c>=58 mmol/mol 1.95 (1.83-2.07) 2.33 (2.08-2.61) 1.90 (1.78-2.02) 1.85 (1.72-1.99) 1.87 (1.76-1.99) 




Diagnosed < 1 
year ago 1.72 (1.50-1.97) 1.66 (1.27-2.16) 1.68 (1.46-1.94) 1.67 (1.43-1.96) 1.74 (1.52-1.99) 








Diagnosed < 1 
year ago 2.82 (2.09-3.81) 2.22 (1.15-4.27) 2.87 (2.11-3.91) 2.35 (1.61-3.43) 2.81 (2.08-3.79) 








30-60 1.33 (1.28-1.40) 1.49 (1.36-1.63) 1.33 (1.27-1.39) 1.37 (1.30-1.44) 1.33 (1.27-1.39) 
 Estimated GFR <30 2.52 (2.33-2.72) 2.98 (2.57-3.46) 2.47 (2.28-2.68) 2.50 (2.29-2.74) 2.50 (2.31-2.70) 
Liver disease  1.75 (1.51-2.03) 1.92 (1.48-2.49) 1.69 (1.44-1.97) 1.75 (1.48-2.07) 1.75 (1.51-2.03) 
Stroke/dementia  2.16 (2.06-2.27) 1.74 (1.58-1.93) 2.12 (2.01-2.22) 2.16 (2.05-2.28) 2.16 (2.06-2.27) 
Other neurological 
disease  2.58 (2.38-2.79) 2.26 (1.91-2.68) 2.50 (2.30-2.73) 2.53 (2.31-2.77) 2.58 (2.38-2.80) 
Organ transplant  3.55 (2.79-4.52) 2.57 (1.60-4.13) 3.72 (2.91-4.75) 3.48 (2.64-4.58) 3.48 (2.74-4.44) 
Asplenia  1.34 (0.98-1.83) 1.87 (1.13-3.11) 1.29 (0.93-1.80) 1.35 (0.95-1.92) 1.33 (0.98-1.82) 
Rheumatoid/Lupus/ 




 1.70 (1.34-2.16) 1.98 (1.32-2.96) 1.62 (1.26-2.09) 1.66 (1.27-2.16) 1.67 (1.31-2.11) 
FOOTNOTES: Models adjusted for age using a 4-knot cubic spline age spline, except for estimation of age group hazard ratios. 
*Ethnicity hazard ratios in primary analysis estimated from a model restricted to those with recorded ethnicity. **OCS = oral 
1 
corticosteroids. Recent OCS use defined as in the year before baseline. ***HbA1c classification based on latest. ****GFR = glomerular 
filtration rate in ml/min/1.73m2, based on most recent serum creatinine measure 


